Teva Pharmaceutical says CEO Jeremy Levin has resigned

30 October 2013

Israel-based Teva Pharmaceutical Industries (NYSE: EVA), say that, despite its recent denials of a rift with its chief executive, its board of directors has agreed with Jeremy Levin that he will step down as president and CEO, just 18 months after assuming the positions at Teva, the world’s largest generics firm.

The board has named Eyal Desheh, Teva's executive vice president and chief financial officer, to fill both roles on an interim basis, effective immediately, and it has formed a committee that will promptly begin to search for a permanent successor.

On Sunday evening, Israel’s Channel 2 News reported that there were severe tensions between Dr Levin and Teva chairman Phillip Frost and that they could not work together and that Dr Levin had threatened to resign. Teva denied the report, commented Israeli newspaper Globes. Trading in Teva's shares was suspended on TASE this morning following the unexpected announcement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK